NEW YORK (GenomeWeb) – Opko Health and Bio-Reference Laboratories today announced a definitive merger agreement valued at about $1.47 billion. 

Under the terms of the deal, each Bio-Reference shareholder will receive 2.75 shares of Opko's common stock for each share of Bio-Reference stock. Based on Opko's closing price of $19.12 per share on June 3, the transaction is estimated to be worth $52.58 per share of Bio-Reference's common stock, the firms said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.